Titan Biotech Bonus Shares will be issued in a 1:4 ratio, with the company fixing October 23, 2026, as the record date to determine eligible shareholders.
Under the announced terms, investors holding four existing shares will be entitled to receive one additional share, subject to the applicable eligibility rules.
The company has finalised the schedule following in-principle approval from BSE.
The bonus issue was earlier approved by shareholders at Titan Biotech’s 34th Annual General Meeting held on September 29, 2026.
Titan Biotech Bonus Shares: Key Dates and Ratio
Titan Biotech has set October 23, 2026, as the record date for its bonus share issue.
Shareholders whose names appear as eligible holders under the applicable rules on the record date will qualify for the additional shares.
The bonus ratio is 1:4, meaning one new fully paid-up equity share will be issued for every four existing fully paid-up equity shares held.
Each bonus share will have a face value of Rs 2.
The company plans to issue a total of 1,03,29,625 bonus equity shares.
The deemed date of allotment is October 26, 2026, and the new shares are scheduled to become available for trading from October 27, subject to the completion of the required process.
How the Bonus Share Issue Will Work
A bonus issue allows a company to distribute additional shares to eligible existing shareholders without requiring them to purchase those shares separately.
The entitlement is based on the number of shares held and the bonus ratio announced by the company.
For example, an investor holding 40 eligible shares would be entitled to receive 10 bonus shares under a 1:4 ratio.
The additional shares increase the number of shares held, but a bonus issue by itself does not guarantee a rise in the overall value of an investor’s holding.
Titan Biotech Bonus Shares will be allotted according to the announced ratio and schedule.
Investors should check their demat account and the company’s official announcements for confirmation of the credit and trading status.
What Investors Should Keep in Mind
The record date determines which shareholders qualify for the bonus issue under the applicable rules.
Investors should verify the company’s official exchange filing and confirm the relevant eligibility requirements with their broker or depository participant.
A bonus issue should not be treated as a guaranteed profit or a signal that a stock’s market price will rise.
Market prices can move in either direction, and investors should assess the company’s financial performance, valuation and risk before making investment decisions.
With October 23 fixed as the record date, shareholders can refer to Titan Biotech’s official announcements for the final allotment and trading timeline.
The deemed allotment date is October 26, with trading in the bonus shares scheduled to begin on October 27, 2026.
